Helping patients attain and maintain asthma control: reviewing the role of the nurse practitioner.

42 , 43 In a separate study by Holgate et al, 44 exacerbation rates in patients treated with omalizumab were 35%–45% lower than the rates observed in the patients treated with placebo, although these differences did not reach statistical significance. 44 Safety concerns Inhaled corticosteroids The NAEPP guidelines state that ICSs are generally well tolerated and safe when used at the recommended doses. 7 However, long-term use (>1 year) of high doses of ICSs, particularly if given in combination with frequent courses of oral corticosteroids, ma

also in 111,027 other papers